Recent Updates
Recently added Catalysts

NNC0662-3168

Phase 1/2

Overweight | Small Molecules | Other |Novo Nordisk A/S|Trials Updated: Nov 17, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment300

FDA Designations

No designations recorded

NNC0662-3168 clinical trials

NNC0662-3168 · 1 trial · 3 indications

Phase 1/2 1
NCT07940803A Research Study of a New Medicine NNC0662-3168 for Weight Management and Type 2 DiabetesOverweight
NOT YET_RECRUITING300 Analytics
PHASE1/PHASE2NOT YET_RECRUITING
A Research Study of a New Medicine NNC0662-3168 for Weight Management and Type 2 Diabetes
OverweightUnlock trial analytics

Study Endpoints

Primary Endpoints

Part A: Number of treatment-emergent adverse events (TEAEs)
From dosing on day 1 upto 29 days

Number of events.

Part B: Number of treatment-emergent adverse events (TEAEs)
From dosing at week 0 up to 39 weeks

Number of events.

Part C: Change in body weight
From baseline (week 0) to week 36

Measure in Percentage (%) change in body weight

Part D: Change in glycated haemoglobin (HbA1c)
From baseline (week 0) to week 28

Measured in percentage of glycated haemoglobin.

Secondary Endpoints

Part A: Area under the NNC0662-3168 concentration-time curve
From pre-dose on day 1 upto 29 days
Part A: Maximum concentration of NNC0662-3168
From pre-dose on day 1 upto 29 days
Part B: Area under the NNC0662-3168 concentration-time curve
From pre dose on day 1 upto 39 weeks
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
NNC0662-3168 (Test product-A)EXPERIMENTALParticipants will receive NNC0662-3168 by subcutaneous injection in Part A to Part D.
Placebo matched to NNC0662-3168 (Test product-A)PLACEBO_COMPARATORParticipants will receive placebo by subcutaneous injection in Part A to Part C.
Product-BACTIVE_COMPARATORParticipants will receive active comparator (product-B) by subcutaneous injection in Part C to Part D.

Interventions

NameTypeDescription
NNC0662-3168 (Test product-A)DRUGNNC0662-3168 is administered subcutaneously.
Placebo matched to NNC0662-3168 (Test product-A)DRUGPlacebo is administered subcutaneously.
Active Comparator (Product-B)DRUGActive Comparator is administered subcutaneously.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 75 Years
SexALL
Healthy VolunteersYes
Study Sites2

Inclusion Criteria: Male or female (sex at birth). * Age at the time of signing the informed consent: * For Part A: 18-55 years (both inclusive). * For Part B: 18-55 years (both inclusive). * For Part C: 18-65 years (both inclusive). * For Part D: 18-75 years (both inclusive). Part D : * Diagnos...

Countries:United States
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWNov 17, 2026NCT07940803NEW_TRIAL: changed
LOWNov 17, 2026NCT07940803NEW_TRIAL: changed